Rethinking cancer clinical trials for COVID-19 and beyond.

Nat Cancer

Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.

Published: June 2020

The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential to ensure the resilience of clinical cancer research and optimize patient-centered care.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258610PMC
http://dx.doi.org/10.1038/s43018-020-0083-xDOI Listing

Publication Analysis

Top Keywords

rethinking cancer
4
cancer clinical
4
clinical trials
4
trials covid-19
4
covid-19 risks
4
risks posed
4
posed patients
4
patients cancer
4
cancer current
4
current covid-19
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!